Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00498537 · ClinicalTrials.gov registry record · NA
Spironolactone for Reducing Proteinuria in Diabetic Nephropathy
A NA study, sponsored by US Department of Veterans Affairs.
- Completed
- Registry status
- NA
- Development phase
- 30
- Enrollment target
NCT00498537 is a NA study that has completed, run by US Department of Veterans Affairs. The registered enrollment target is 30 participants.
The verdict
NCT00498537, a NA study, has completed, sponsored by US Department of Veterans Affairs.
- COMPLETED
- Registry status
- NA
- Development phase
- 30 participants
- Enrollment target
Study Summary
Introduction: Aldosterone seems to have deleterious effects on the kidneys. Many animal studies and few clinical trials now have shown that suppression of aldosterone by aldosterone receptor blockers ameliorated these effects. Method: In a double-blind, cross over study, 24 patients with diabetic nephropathy who were already receiving either ACE inhibitor(lisinopril 20-40 mg/day ) or ARB( losartan 25-100 mg/day )were given spironolactone( 25 mg during the first month and 50 mg during the second and third month if serum K remained ok) or matching placebo with 1 month of washout in between. All patients were from a single center and exclusively male veterans. Blood pressure, serum creatinine, serum K and spot urine protein/creatinine were measured at the beginning and end of each study period. The study was started in May of 2003 and completed in May 2006.
Interventions
- DRUG spironolactone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2003-01 |
| Est. Completion | 2006-06 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00498537
The ClinicalTrials.gov registry entry for NCT00498537 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is US Department of Veterans Affairs, which has 632 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which spironolactone is the first listed.
NCT00498537 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00498537 about?
NCT00498537 is a clinical study titled "Spironolactone for Reducing Proteinuria in Diabetic Nephropathy". Introduction: Aldosterone seems to have deleterious effects on the kidneys. Many animal studies and few clinical trials now have shown that suppression of aldosterone by aldosterone receptor blockers ameliorated these effects. Method: In a double-blind, cross over study, 24 patients with diabetic n...
What is the current status of trial NCT00498537?
This trial is currently completed. It is a NA study. The enrollment target is 30 participants. The study started on 2003-01. Estimated completion is 2006-06.
What interventions are being tested in trial NCT00498537?
The interventions under investigation include: spironolactone (DRUG).
Who is sponsoring clinical trial NCT00498537?
This trial is sponsored by US Department of Veterans Affairs, which has 632 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.